PDUFA VII Talks To Begin With COVID-19, Other Familiar Issues To Consider
Executive Summary
US FDA staffing problems and patient engagement enhancements will be listed as priorities during reauthorization kick-off meeting.
You may also be interested in...
Would An Independent Analysis Of US FDA's Pandemic Response Find Transformative Effect?
Group of outside experts could help the agency determine the pandemic-inspired practices and regulatory changes to keep, former commissioner von Eschenbach says.
Does US FDA Need An Independent Commission To Analyze Its Pandemic Response?
Group of outside experts could help the agency determine the pandemic-inspired practices and regulatory changes to keep, former commissioner von Eschenbach says.
US FDA’s COVID Master Protocol Guidance To Maintain Influence Post-Pandemic
Agency seeking comment on document intended to replace the just-issued guidance on COVID-19 treatment development as FDA stresses the value of master protocols for developing clinical knowledge.